search
Back to results

Telemonitoring in NIV MND (OptNIVent) (OptNIVent)

Primary Purpose

Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Telemonitoring via Careportal®
Sponsored by
Liverpool University Hospitals NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Motor Neuron Disease, Amyotrophic Lateral Sclerosis focused on measuring non-invasive ventilation, Telehealth, Telemonitoring

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria (Patients):

  • Confirmed diagnosis of MND with respiratory muscle weakness
  • Adults who are capable of informed consent
  • Patients for whom we anticipate survival of 6 months or more
  • Able to communicate with an interviewer. Alternative communication methods will be used as required in order to mitigate communication difficulties.

Exclusion Criteria (Patients):

  • Patients who have declined NIV

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Other

    Arm Label

    Telemonitoring via Careportal®

    Arm Description

    Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.

    Outcomes

    Primary Outcome Measures

    Acceptability - Qualitative data through semi-structured interviews and focus groups
    Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
    Usability - Qualitative data through semi-structured interviews and focus groups
    Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.

    Secondary Outcome Measures

    Patient Reported Outcome Measurement - Neurological Fatigue Index for MND
    13-item questionnaire assessing fatigue experienced by people with motor neurone disease. The questionnaire consists of two sub-scales: Weakness sub-scale and Energy sub-scale. Eight items make up the Summary Fatigue scale with the total scores range from 0 to 24. Higher scores indicate higher levels of fatigue
    Patient Reported Outcome Measurement - Epworth Sleepiness Scale
    8-item questionnaire to measure general levels of sleepiness. Total scores range from 0 to 24. Higher scores indicate higher levels of sleepiness.
    Patient Reported Outcome Measurement - Dyspnoea-12
    12-item questionnaire to measure overall breathlessness severity. Total scores range from 0 to 36. Higher scores indicate higher breathless severity.
    Patient Reported Outcome Measurement - revised Amyotrophic Lateral Sclerosis Functional Rating Scale
    12-item questionnaire to monitor the disease progression covering bulbar, motor and respiratory function. Total scores range from 0 to 48. Higher scores indicate better function.
    Patient Reported Outcome Measurement - Hospital Anxiety and Depression Scale
    14-item questionnaire to measure anxiety and depression levels. The questionnaire consists of anxiety sub-scale and depression sub-scale. Scores for each sub-scale range from 0 to 21. Higher scores indicate greater anxiety/depression levels.
    Patient Reported Outcome Measurement - the World Health Organization Quality of Life Scale-BREF
    26-item questionnaire consists of Physical Health domain, Psychological domain, Social relationships domain, and Environment domain in addition to Overall QoL (1-item) and General Health (1-item) facets. Total scores range from 0 to 100. Higher scores indicate indicate higher quality of life.
    Patient Reported Outcome Measurement - 5-level EQ-5D
    The questionnaire consists of 5-item to measure health based on five domains: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 levels indicating worsening health, from having no problems to having severe problems. The questionnaire also contain one visual analogue scale measuring health-reported health: 0 indicates worst health while 100 indicates the best health.
    Patient Reported Outcome Measurement - General Satisfaction
    6-item General Satisfaction sub-scale from Patient Satisfaction Questionnaire. Total scores range from 6 to 30. Higher scores indicate greater satisfaction.
    Patient Reported Outcome Measurement - Access, Availability and Convenience
    12-item Access, Availability and Convenience sub-scale from Patient Satisfaction Questionnaire. Total scores range from 12 to 60. Higher scores indicate greater access, availability and convenience.
    Self-Reported Outcome Measurement - Caregiving Distress Scale
    17-item questionnaire to measure caregiver distress, covering five dimensions: Relationship distress, Emotional burden, Social impact, Care-receiver demands, and Personal cost. Total scores range from 0 to 68. Higher scores indicate greater distress.
    Service evaluation
    Patient Level Information and Costing System (PLICS)

    Full Information

    First Posted
    September 21, 2021
    Last Updated
    March 18, 2022
    Sponsor
    Liverpool University Hospitals NHS Foundation Trust
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05299372
    Brief Title
    Telemonitoring in NIV MND (OptNIVent)
    Acronym
    OptNIVent
    Official Title
    Optimising the Management of Ventilated Patients and Quality of Life in Motor Neurone Disease: a Pilot Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    April 25, 2022 (Anticipated)
    Primary Completion Date
    October 31, 2022 (Anticipated)
    Study Completion Date
    December 31, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Liverpool University Hospitals NHS Foundation Trust

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This is a feasibility study of telemonitoring system for people with MND/ALS, who are on NIV, via a call centre operated by a local clinical commissioning group.
    Detailed Description
    This study will test the feasibility of previously developed Telehealth system, using a device called Careportal®, to monitor people with MND/ALS who are using non-invasive ventilation (NIV). The Careportal® is a CE marked portable tablet computer device allowing telecommunication between patients and their care team through bespoke question sets, overnight oximetry test, and patient-ventilator interaction(PVI) data. Previously, the weekly telemonitoring via Careportal® was found to be an effective method to monitor symptom changes, allowing clinicians to optimise the care of ventilated patients with MND. This study will assess the practicality of using Careportal® in the care of ventilated patients with MND by monitoring patients through a patient support call centre. The call centre will screen the data and liaise with appropriate clinicians regarding changes of symptoms.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Motor Neuron Disease, Amyotrophic Lateral Sclerosis
    Keywords
    non-invasive ventilation, Telehealth, Telemonitoring

    7. Study Design

    Primary Purpose
    Supportive Care
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    15 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Telemonitoring via Careportal®
    Arm Type
    Other
    Arm Description
    Participants will be prompted by the device to answer two sets of questions every week: 10 items (1 nested) in the morning and 16 items (4 nested) in the evening. Also on a weekly basis, patients will be prompted to perform overnight oximetry test, and upload patient-ventilator interaction data (PVI) via Careportal®.
    Intervention Type
    Other
    Intervention Name(s)
    Telemonitoring via Careportal®
    Intervention Description
    The question sets and overnight oximetry results will be monitored and screened by a call centre commissioned by the Liverpool Clinical Commissioning Group (LCCG). The call centre will screen the weekly data and contact clinicians where appropriate (i.e. NIV team, MND specialist nurse, or patient's GP). PVI data will be examined by NIV physiotherapists, where required, following the contact from LCCG to ensure the maximum benefits of NIV to patients.
    Primary Outcome Measure Information:
    Title
    Acceptability - Qualitative data through semi-structured interviews and focus groups
    Description
    Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
    Time Frame
    Qualitative data will be conducted at 3-month
    Title
    Usability - Qualitative data through semi-structured interviews and focus groups
    Description
    Qualitative data will be collected through focus groups with participants, their lay caregivers, and clinicians. Separate focus groups will be conducted for the three participant groups with an option of individual interviews for patients and lay caregivers.
    Time Frame
    Qualitative data will be conducted at 3-month
    Secondary Outcome Measure Information:
    Title
    Patient Reported Outcome Measurement - Neurological Fatigue Index for MND
    Description
    13-item questionnaire assessing fatigue experienced by people with motor neurone disease. The questionnaire consists of two sub-scales: Weakness sub-scale and Energy sub-scale. Eight items make up the Summary Fatigue scale with the total scores range from 0 to 24. Higher scores indicate higher levels of fatigue
    Time Frame
    Baseline and then 6-weekly up to 24 weeks
    Title
    Patient Reported Outcome Measurement - Epworth Sleepiness Scale
    Description
    8-item questionnaire to measure general levels of sleepiness. Total scores range from 0 to 24. Higher scores indicate higher levels of sleepiness.
    Time Frame
    Baseline and then 6-weekly up to 24 weeks
    Title
    Patient Reported Outcome Measurement - Dyspnoea-12
    Description
    12-item questionnaire to measure overall breathlessness severity. Total scores range from 0 to 36. Higher scores indicate higher breathless severity.
    Time Frame
    Baseline and then 6-weekly up to 24 weeks
    Title
    Patient Reported Outcome Measurement - revised Amyotrophic Lateral Sclerosis Functional Rating Scale
    Description
    12-item questionnaire to monitor the disease progression covering bulbar, motor and respiratory function. Total scores range from 0 to 48. Higher scores indicate better function.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Patient Reported Outcome Measurement - Hospital Anxiety and Depression Scale
    Description
    14-item questionnaire to measure anxiety and depression levels. The questionnaire consists of anxiety sub-scale and depression sub-scale. Scores for each sub-scale range from 0 to 21. Higher scores indicate greater anxiety/depression levels.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Patient Reported Outcome Measurement - the World Health Organization Quality of Life Scale-BREF
    Description
    26-item questionnaire consists of Physical Health domain, Psychological domain, Social relationships domain, and Environment domain in addition to Overall QoL (1-item) and General Health (1-item) facets. Total scores range from 0 to 100. Higher scores indicate indicate higher quality of life.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Patient Reported Outcome Measurement - 5-level EQ-5D
    Description
    The questionnaire consists of 5-item to measure health based on five domains: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression. Each domain has 5 levels indicating worsening health, from having no problems to having severe problems. The questionnaire also contain one visual analogue scale measuring health-reported health: 0 indicates worst health while 100 indicates the best health.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Patient Reported Outcome Measurement - General Satisfaction
    Description
    6-item General Satisfaction sub-scale from Patient Satisfaction Questionnaire. Total scores range from 6 to 30. Higher scores indicate greater satisfaction.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Patient Reported Outcome Measurement - Access, Availability and Convenience
    Description
    12-item Access, Availability and Convenience sub-scale from Patient Satisfaction Questionnaire. Total scores range from 12 to 60. Higher scores indicate greater access, availability and convenience.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Self-Reported Outcome Measurement - Caregiving Distress Scale
    Description
    17-item questionnaire to measure caregiver distress, covering five dimensions: Relationship distress, Emotional burden, Social impact, Care-receiver demands, and Personal cost. Total scores range from 0 to 68. Higher scores indicate greater distress.
    Time Frame
    Baseline and at 3-month and 6-month
    Title
    Service evaluation
    Description
    Patient Level Information and Costing System (PLICS)
    Time Frame
    At the end of study i.e. at 6-month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria (Patients): Confirmed diagnosis of MND with respiratory muscle weakness Adults who are capable of informed consent Patients for whom we anticipate survival of 6 months or more Able to communicate with an interviewer. Alternative communication methods will be used as required in order to mitigate communication difficulties. Exclusion Criteria (Patients): Patients who have declined NIV
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Hikari Ando, PhD
    Phone
    0151529
    Email
    hikari.ando@nhs.net
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Robert M Angus, MRCP, FRCP
    Organizational Affiliation
    Liverpool University Hospitals NHS Foundation Trust
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    30912468
    Citation
    Ando H, Ashcroft-Kelso H, Halhead R, Young CA, Chakrabarti B, Levene P, Cousins R, Angus RM. Incorporating self-reported questions for telemonitoring to optimize care of patients with MND on noninvasive ventilation (MND OptNIVent). Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):336-347. doi: 10.1080/21678421.2019.1587630. Epub 2019 Mar 26.
    Results Reference
    background

    Learn more about this trial

    Telemonitoring in NIV MND (OptNIVent)

    We'll reach out to this number within 24 hrs